The Child and Adolescent NeuroDevelopment Initiative

On December 7, 2015, Neuren Pharmaceuticals announced results of their Phase 2 clinical trial of trofinetide in individuals with Fragile X syndrome. CANDI was one of the sites at which the study was conducted. The results show that individuals on the drug tolerated it well. The company also reports that improvements were seen several core symptoms of Fragile X syndrome. Neuren plans to meet with the FDA in early 2016 to discuss the results.

Read more in the Neuren Pharmaceuticals announcement (PDF).

Who We Are

The Child and Adolescent NeuroDevelopment Initiative (CANDI) is a research program in the Department of Psychiatry at the University of Massachusetts Medical School dedicated to neuroimaging and treatment studies of individuals with mood disorders, trauma, early onset schizophrenia and developmental disabilities including autism and fragile X. Find out more.

 About CANDI Button  Studies Button  Family Resources Button

CANDI logo  Find us on Facebook and Twitter.

▴ Back To Top
Section Menu To Top